Skip to main content
Clinical Trials/DRKS00010557
DRKS00010557
Recruiting
Phase 2

Effectiveness of dayclinic treatment for adolescents with personality developmental disorders with techniques of the transference focused psychotherapy for adolescents (TFP-A)

niklinik KölnKlinik für Kinder- und Jugendpsychiatrie0 sites160 target enrollmentAugust 27, 2020

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
F60-F69
Sponsor
niklinik KölnKlinik für Kinder- und Jugendpsychiatrie
Enrollment
160
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 27, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niklinik KölnKlinik für Kinder- und Jugendpsychiatrie

Eligibility Criteria

Inclusion Criteria

  • For inclusion into the study a written consent form for the study is necessary signed after informed consent (about the procedure of the study as well as their voluntary involvement and the freedom to terminate the participation at any time) by the adolescent who is above 14 years of age or by the parents for patients who are 13 years of age. All patients need to be between 13 to 17 years of age, they have to fulfill at least probable criteria for a personality disorder based on the International Personality Disorder Examination, conducted by a reliable interviewer.
  • Inclusion criteria for target sample and control sample: Existance of a personality disorder on the Basis of DSM\-IV (IPD)
  • Inclusion criteria for target sample: Treatment in dayclinic.
  • Inclusion criteria for Waitinggroup: Existence of a personality disorder and written consent to participate.

Exclusion Criteria

  • Exclusion criteria are missing reading knowledge of the German language; an IQ below 70, a disorder from the schizophrenic spectrum; any other disorders of perception, cognition and affectivity which influence neuropsychological testing; a change of medication which influences the CNS during the dayclinic treatment program. Medication which has already been given before inclusion into the program does not fulfill an exclusion criterion.

Outcomes

Primary Outcomes

Not specified

Similar Trials